A Business at a Glance
0 of 5 daily views used (5 remaining). Sign up free for 10 daily views, or try AAPL for a full preview.
We are a clinical-stage biopharmaceutical company focused on the development of novel, first-in-class or best-in-class therapies for metabolic and endocrine disorders. In January 2022, we announced the initiation of a Phase 1 single ascending dose, or SAD, and multiple ascending dose, or MAD, clinical trial of VK2735, a novel dual agonist of the glucagon-like peptide 1, or GLP-1, and glucose-dependent insulinotropic polypeptide, or GIP, receptors. VK2735 is being developed in both oral and subcutaneous formulations for the potential treatment of various metabolic disorders such as obesity. In March 2023, we announced the completion of the Phase 1 trial. The study was a randomized, double-blind, placebo-controlled, SAD and MAD study in healthy adults. The primary objectives of the study included evaluation of the safety and tolerability of single and multiple doses of VK2735 delivered subcutaneously and the identification of VK2735 doses suitable for further clinical development.
| Metric | TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 | 0 |
| Net Income | -360M | -360M | -110M | -86M | -69M | -55M |
| EPS | $-3.19 | $-3.19 | $-1.01 | $-0.91 | $-0.90 | $-0.71 |
| Free Cash Flow | -279M | -279M | -88M | -73M | -48M | -48M |
| ROIC | -65.6% | -47.3% | -16.6% | -24.7% | -47.4% | -26.4% |
| Gross Margin | - | - | - | - | - | - |
| Debt/Equity | 0.00 | 0.00 | - | 0.00 | 0.01 | - |
| Dividends/Share | $0.00 | - | - | - | - | - |
| Operating Income | -393M | -393M | -151M | -101M | -70M | -56M |
| Operating Margin | 0.0% | - | - | - | - | - |
| ROE | -56.3% | -47.3% | - | -24.7% | -47.4% | - |
| Shares Outstanding | 113M | 113M | 109M | 94M | 77M | 77M |
Viking Therapeutics, Inc. passes 0 of 9 quality checks, indicating weak fundamentals.
Viking Therapeutics, Inc. (VKTX) has a 5-year average return on invested capital (ROIC) of -32.5%. This is below average and may indicate limited pricing power.
Viking Therapeutics, Inc. (VKTX) has a market capitalization of $3.9B. It is classified as a mid-cap stock.
Viking Therapeutics, Inc. (VKTX) does not currently pay a regular dividend.
Viking Therapeutics, Inc. (VKTX) operates in the Pharmaceutical Preparations industry, within the Healthcare sector.
Viking Therapeutics, Inc. (VKTX) generated $-279 million in free cash flow in its most recent fiscal year. Negative free cash flow may indicate heavy investment or operational challenges.
Viking Therapeutics, Inc. (VKTX) has a debt-to-equity ratio of 0.00. This indicates a conservatively financed balance sheet.
Viking Therapeutics, Inc. (VKTX) reported earnings per share (EPS) of $-3.19 in its most recent fiscal year.
Viking Therapeutics, Inc. (VKTX) has a return on equity (ROE) of -47.3%. A negative ROE may indicate losses or negative equity.
The Ledger Terminal provides 12 years of financial data for Viking Therapeutics, Inc. (VKTX), sourced directly from SEC EDGAR filings. This includes income statements, balance sheets, cash flow statements, and key financial ratios.
Viking Therapeutics, Inc. (VKTX) has a book value per share of $5.67, based on its most recent annual SEC filing.